Author:
Olson Michael D.,Flick Randall
Reference8 articles.
1. Caldwell JE, Szenohradszky J, Segredo V, et al. The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. J Pharmacol Exp Ther. 1994;270:1216–22.
2. Lebrault C, Berger JL, D’Hollander AA, et al. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. Anesthesiology. 1985;62:601–5.
3. Pirttiaho HI, Sotaniemi EA, Pelkonen RO, et al. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol. 1982;22:441–5.
4. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med. 1996;334:168–75.
5. Alloul K, Whalley DG, Shutway F, et al. Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. Anesthesiology. 1996;84:330–9.